CatSci Presents

Innovations in Peptide Science 2025

BioCity, Nottingham, UK
July 1st 2025

Join academic experts, biotech pioneers, and drug development specialists for a one-day event focused on the next generation of peptide-based therapeutics. This conference will bring together leaders in the peptide community across academia, industry and pharma to explore the latest scientific and clinical dimensions of peptide innovation.

Key topics include

Novel peptide synthesis platforms and discovery strategies
Rational design and therapeutic application of peptides
Advanced strategies for peptide cyclisation
Peptides in catalysis and biocatalysis
Peptide conjugation strategies
Methods towards a greener future in peptide synthesis and purification

Register Now

Featured speakers

Don Wellings, Founder and Managing Director (SpheriTech Ltd)
Andrew Jamieson, Professor of Chemical Biology (University of Glasgow)
Jefferson Revell, Principal Scientist (AstraZeneca)
Nick Mitchell, Associate Professor (University of Nottingham)
Mark Eccleston, CEO (ValiRx)
Anna Peacock, Reader in Bioinorganic Chemistry (University of Birmingham)
Nara Daubeney, CEO and Co-Founder (Phaim Pharma)
Drew Thomson, Lecturer (University of Glasgow)
Dominik Sarma, Senior Market Manager (Gyros Protein Technologies)
Peter Ridgway, Co-Founder (Reach Separations)
Jordan Fletcher, Technical Director of Peptides (CatSci)
Cameron Thorpe, Oligonucleotides Team Lead (CatSci)

Full agenda will be available soon

Badge Registration Form

Badge registration is mandatory for all attendees, entry will not be granted without a badge. There is no cost to register for this event but spaces are limited so registering as early as possible using the form below is strongly recommended.

Name(Required)

First Last

Email(Required)

Company(Required)

Job Title

Country(Required)

Dietary restrictions, allergies, or accessibility requirements

Who Should Attend

This event is designed for professionals involved in the discovery, development, and manufacture of peptide-based therapeutics and complex synthetic medicines.

You should attend if you are:

A scientific leader or project head advancing peptide, oligonucleotide, or hybrid modality programs
A drug developer working on the integration of peptides with other therapeutic technologies
A CSO, VP R&D, or Director of CMC seeking insight into emerging capabilities
Business strategy leaders seeking insight into the future of synthetic modality innovation
Heads of Peptide Chemistry, Principal Scientists, and Research Fellows exploring novel synthesis platforms

Join us to explore how scientific innovation in peptides is building the next generation of complex synthetic medicines.